Glass House Brands Inc. (GLAS) is a California-focused, vertically integrated cannabis company rather than an ETF, so its "stock price target" is best assessed through analyst research. Three current targets were reviewed, ranging from a low of $15 to a high of $17. Their arithmetic mean is $16.00, which serves as the central target here.
The individual views differ only modestly. Lake Street analyst Ryan Meyers initiated coverage with a Buy rating and a $17 target in July 2026, citing the company's low-cost Camarillo greenhouse platform. Canaccord lowered its target to $15 from $16 in August 2026 while keeping a Buy rating, following mixed second-quarter results and management's reiterated guidance for 2026 biomass production of 1.0 million pounds. A third target at $16 completes the narrow band.
Importantly, data providers caution that GLAS's share price has fallen sharply in the past year and that these price targets "may not have had time to catch up." Because coverage is thin and the $15–$17 range is unusually tight for such a volatile name, the average analyst price target should be read as a directional view rather than a precise short-term forecast.
GLAS last traded near $3.19, toward the bottom of a 52-week range of approximately $3.10 to $13.93. From that level, a move to $16 represents upside of about 401%, which must be described as a very large move. The path would require not just a recovery of the recent decline but a decisive break above levels the stock last saw months ago.
The company generated trailing revenue of roughly $177 million but remains unprofitable, with a trailing net loss near $64 million and negative EPS (earnings per share). A $16 valuation implies a market capitalization far above the current figure of around $300 million, meaning the market would need to reprice the company's growth and profitability outlook substantially.
GLAS sits essentially at its 52-week low of about $3.10, which is the immediate support level to watch. Below that, the stock would be in uncharted multi-year territory. On the upside, the prior breakdown through the $8–$10 zone has left meaningful resistance levels at those former trading ranges well before the $16 target is approached. The round-number levels of $5 and $10 are likely psychological hurdles, while the 52-week high near $13.93 marks the most significant prior peak. The technical picture underscores just how far the stock must climb to validate the analyst-derived target.
Analyst price targets typically reflect a research horizon of about 12 months, though the individual reports here carry slightly different dates and rationales, and none should be treated as a timing guarantee. Investors should monitor the next earnings report (estimated for November 11, 2026), progress toward the 1.0-million-pound biomass target, gross-margin trends, any analyst target revisions, and developments in federal cannabis regulation. Because coverage is thin, a single rating change can move the consensus meaningfully.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile name like GLAS, such tools can help traders discover opportunities, monitor positions, and spot shifting trends more efficiently than manual chart review alone. Explore the AI Daily Buy/Sell Signals to see how automated monitoring can complement your own research.
The $16 central target for GLAS is the average of three analyst price targets spanning $15 to $17, implying a roughly 401% gain from the recent price near $3.19 — a very large move. The bull case rests on low-cost cultivation, biomass growth, and potential regulatory reform, while the bear case centers on persistent losses, declining revenue, and federal legal uncertainty. The narrow analyst range contrasts sharply with the stock's recent volatility, suggesting the targets may not fully reflect the latest market reality. Reaching $16 would require a fundamental repricing of the company's growth and profitability, and investors should track earnings, production guidance, and analyst revisions closely. No outcome is guaranteed, and this analysis is not an investment recommendation.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, GLAS has been closely correlated with TRLV. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if GLAS jumps, then TRLV could also see price increases.
| Ticker / NAME | Correlation To GLAS | 1D Price Change % | ||
|---|---|---|---|---|
| GLAS | 100% | -0.43% | ||
| TRLV - GLAS | 69% Closely correlated | +1.95% | ||
| CGC - GLAS | 63% Loosely correlated | -6.67% | ||
| TLRY - GLAS | 59% Loosely correlated | -3.63% | ||
| CRON - GLAS | 52% Loosely correlated | +3.35% | ||
| ACB - GLAS | 50% Loosely correlated | -0.25% | ||
More | ||||
| Ticker / NAME | Correlation To GLAS | 1D Price Change % |
|---|---|---|
| GLAS | 100% | -0.43% |
| GLAS (2 stocks) | 88% Closely correlated | -1.71% |
| Pharmaceuticals (153 stocks) | -1% Poorly correlated | -0.52% |
| Pharmaceuticals: Generic (83 stocks) | -2% Poorly correlated | +0.01% |